Topic: Medarex Inc.
NEW YORK (Reuters) - The Chief Executive of Bristol-Myers Squibb Co said the company intends to remain "100 percent" in prescription medicines and is prepared to use its $10 billion cash hoard to gain new drugs through moderate size deals with other drugmakers ...
Last month, Morphosys (MPHSF. PK) reported its 2010 earnings, which seems like a good point of revisiting the stock. Last time I wrote about...
In its earnings release last week, Seattle Genetics (SGEN) did not surprise anyone with the financial guidance and expected timelines for approval...
Equities research analysts at Barclays PLC (NYSE: BCS) boosted its price target on shares of Bristol-Myers Squibb (NYSE: BMY) in a research note to...
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30 -positive lymphoma including Hodgkin's disease .
Ipilimumab (also known as MDX-010 or MDX-101 ) is a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex . On December 10, 2007, Bristol-Myers Squibb and Medarex released the results of three studies on ipilimumab. One of the three studies failed to ...
Jeffries analysts upgraded shares of Bristol-Myers (NYSE :BMY) from “Buy” to “hold” in a research note to investors on Tuesday, citing increased...
Continuing its string of pearls philosophy, Bristol-Myers Squibb (BMY) has agreed to pay in cash for ZymoGenetics, which is developing a hepatitis...
Ipilimumab may improve survival in patients with previously treated metastatic melanoma, but with risk of severe adverse events, according to research published in the Aug. 19 issue of the New England Journal of Medicine.. F. Stephen Hodi, M.D., of the Dana-Farber ...
The hottest theme at this year's 2010 ASCO (American Society of Clinical Oncology) annual meeting was without a doubt cancer immunotherapy, an old paradigm that deals with redirecting the patient's immune system against tumors. Both are monoclonal antibodies originally developed ...
